PE20010992A1 - Formulacion de liberacion sostenida de un inhibidor de ciclooxigenasa-2 - Google Patents

Formulacion de liberacion sostenida de un inhibidor de ciclooxigenasa-2

Info

Publication number
PE20010992A1
PE20010992A1 PE2000001394A PE0013942000A PE20010992A1 PE 20010992 A1 PE20010992 A1 PE 20010992A1 PE 2000001394 A PE2000001394 A PE 2000001394A PE 0013942000 A PE0013942000 A PE 0013942000A PE 20010992 A1 PE20010992 A1 PE 20010992A1
Authority
PE
Peru
Prior art keywords
placement
release
drug
cyclooxygenase
inhibitor
Prior art date
Application number
PE2000001394A
Other languages
English (en)
Inventor
Sreekant Nadkarni
David B Hedden
Subhash Desai
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of PE20010992A1 publication Critical patent/PE20010992A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

SE REFIERE A UNA COMPOSICION ORAL QUE COMPRENDE 1)UN INHIBIDOR DE CICLOOXIGENASA 2 DE BAJA SOLUBILIDAD EN AGUA COMO UN COMPUESTO DE FORMULA I; R3 ES METILO AMINO, R4 ES H, ALQUILO, ALCOXI C1-C4; X ES N, CR5; R5 ES H, HALOGENO; Y Y Z SON C, N, QUE DEFINEN ATOMOS ADYACENTES A UN ANILLO DE 5-6 MIEMBROS COMO CICLOPENTENONA, FURANONA, METILPIRAZOL, ENTRE OTROS; SIENDO OTROS INHIBIDORES CELECOXIB (10mg A 1000mg), DERACOXIB, VALDECOXIB, ROFECOXIB, 5-CLORO-3-(4-METILSULFONIL)FENIL-2-(2-METIL-5-PIRIDINIL)PIRIDINA, 2-(3,5-DIFLUORFENIL)-3-[4-(METILSULFONIL)FENIL]-2-CICLOPENTENO-1-ONA; (S)-6,8-DICLORO-2-TRIFLUOROMETIL)-2H-1-BENZOPIRANO-3-ACIDO CARBOXILICO; 2)POLIMEROS SUSCEPTIBLES DE HINCHAZON O EROSION DONDE LA COMPOSICION PROPORCIONA UN PERFIL DE DISOLUCION DE LIBERACION SOSTENIDA IN VITRO DESPUES DE LA COLOCACION EN UN MEDIO DE DISOLUCION ESTANDAR QUE MUESTRA a)UNA LIBERACION DE 5% A 35% DE LA DROGA 2 HORAS DESPUES DE LA COLOCACION; b)LIBERACION DE 10% A 85% DE LA DROGA 8 HORAS DESPUES DE LA COLOCACION; c)UNA LIBERACION DE 30% A 90% DE LA DROGA 18 HORAS DESPUES DE LA COLOCACION; LA COMPOSICION PUEDE ESTAR PARCIAL O TOTALMENTE a)DISTRIBUIDA EN UNA MATRIZ QUE COMPRENDE DE 0,1% A 40% HIDROXIPROPILMETILCELULOSA CON UNA VISCOSIDAD NOMINAL, 2% DE AGUA, b)CON UN RECUBRIMIENTO QUE COMPRENDE UN POLIMERO SUCEPTIBLE DE HINCHAZON O EROSION
PE2000001394A 1999-12-22 2000-12-22 Formulacion de liberacion sostenida de un inhibidor de ciclooxigenasa-2 PE20010992A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17173899P 1999-12-22 1999-12-22
US18163500P 2000-02-10 2000-02-10
US20226900P 2000-05-05 2000-05-05

Publications (1)

Publication Number Publication Date
PE20010992A1 true PE20010992A1 (es) 2001-09-21

Family

ID=27390016

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001394A PE20010992A1 (es) 1999-12-22 2000-12-22 Formulacion de liberacion sostenida de un inhibidor de ciclooxigenasa-2

Country Status (17)

Country Link
US (2) US20020015735A1 (es)
EP (1) EP1239856A1 (es)
JP (1) JP2003518061A (es)
KR (1) KR20020082473A (es)
CN (1) CN1434713A (es)
AU (1) AU2731401A (es)
BR (1) BR0016629A (es)
CA (1) CA2394222A1 (es)
CZ (1) CZ20022140A3 (es)
IL (1) IL150352A0 (es)
MX (1) MXPA02006150A (es)
NO (1) NO20022988L (es)
NZ (1) NZ519466A (es)
PE (1) PE20010992A1 (es)
PL (1) PL355391A1 (es)
SK (1) SK9022002A3 (es)
WO (1) WO2001045705A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094320A1 (fr) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions therapeutiques permettant de reparer la chondropathie
US20040146561A1 (en) 2001-05-23 2004-07-29 Naoki Sakurai Compositions for promoting healing of bone fracture
US7338971B2 (en) * 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
AU2003243699B2 (en) * 2002-06-21 2009-01-15 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
PA8578501A1 (es) * 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
US20060052432A1 (en) * 2002-09-20 2006-03-09 Julius Remenar Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050163839A1 (en) * 2003-01-29 2005-07-28 Sun Pharmaceutical Industries Limited Oral controlled release pharmaceutical composition containing metaxalone as active agent
SI2821067T1 (en) * 2003-09-12 2018-03-30 Amgen Inc. Quick spray formulation of cinacalcet
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
RS52057B2 (sr) * 2004-08-13 2018-03-30 Boehringer Ingelheim Int Formulacija tablete sa produženim oslobađanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
AU2005271193B2 (en) * 2004-08-13 2011-11-24 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
CA2589167A1 (en) 2004-11-23 2006-06-01 Pliva Hrvatska D.O.O. Extended release pharmaceutical composition of celecoxib
FR2881049B1 (fr) * 2005-01-24 2008-12-26 Vetoquinol Sa Sa Medicament destine a etre administre par voie orale comprenant un inhibiteur de la cyclo-oxygenase-2, et son procede de preparation
EP1858493A4 (en) * 2005-03-14 2010-12-01 Sun Pharmaceutical Ind Ltd SYSTEM FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
ATE480229T1 (de) * 2005-05-24 2010-09-15 Flamel Tech Sa Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung
JP2009501785A (ja) 2005-07-20 2009-01-22 パナセア バイオテック リミテッド 新規な調節放出性医薬製剤シクロオキシゲナーゼ酵素阻害剤
US7964215B1 (en) * 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
EP1988875A2 (en) * 2006-02-10 2008-11-12 Boehringer Ingelheim International GmbH Modified release formulation
WO2008114859A1 (ja) * 2007-03-22 2008-09-25 Astellas Pharma Inc. ピラゾール誘導体を含有する医薬組成物
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
DE102010005849B4 (de) 2010-01-26 2012-04-19 Sig Technology Ag Verfahren zur Herstellung eines Behälters für Nahrungsmittel aus einem aluminiumfreien flächenförmigen Verbund mit einer Innenschicht durch Heissfalten
CN103462920A (zh) * 2012-06-06 2013-12-25 南京亿华药业有限公司 一种口服环加氧酶-2抑制剂塞来昔布的组合物
HUE056810T2 (hu) 2012-11-02 2022-03-28 Murray & Poole Entpr Ltd Szív- és érrendszeri események kezelése és megelõzése kolchicin alkalmazásával
SG11201508571WA (en) 2013-04-16 2015-11-27 Murray And Poole Entpr Ltd Sustained-release formulations of colchicine and methods of using same
TW201639581A (zh) * 2015-05-07 2016-11-16 Univ China Medical 希樂葆（ｃｅｌｅｃｏｘｉｂ）用於製備抗口腔癌的醫藥品之用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9709097A (pt) * 1996-05-17 1999-08-03 Merck & Co Inc Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária
JP2001513563A (ja) * 1997-08-27 2001-09-04 ヘキサル アーゲー 溶解性および生物学的利用能の改良されたメロキシカムの医薬組成物
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib

Also Published As

Publication number Publication date
MXPA02006150A (es) 2004-09-06
EP1239856A1 (en) 2002-09-18
PL355391A1 (en) 2004-04-19
NO20022988D0 (no) 2002-06-20
US20030170303A1 (en) 2003-09-11
CN1434713A (zh) 2003-08-06
NZ519466A (en) 2004-02-27
SK9022002A3 (en) 2003-03-04
IL150352A0 (en) 2002-12-01
CZ20022140A3 (cs) 2002-11-13
CA2394222A1 (en) 2001-06-28
NO20022988L (no) 2002-08-21
BR0016629A (pt) 2002-09-03
KR20020082473A (ko) 2002-10-31
US20020015735A1 (en) 2002-02-07
JP2003518061A (ja) 2003-06-03
AU2731401A (en) 2001-07-03
WO2001045705A1 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
PE20010992A1 (es) Formulacion de liberacion sostenida de un inhibidor de ciclooxigenasa-2
HRP20000380B1 (en) Oral pharmaceutical extended release dosage form
PE20010921A1 (es) Composiciones inhibidoras de ciclooxigenasa-2 que tienen un inicio rapido del efecto terapeutico
HUP0004150A2 (hu) Tirozin kináz receptor antagonista hatású indazolszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0204587A2 (en) 6-position substituted indoline, production and use thereof as a medicament
AR033046A1 (es) Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1, composicion farmaceutica y metodos de preparacion
SE0201659D0 (sv) Modified release pharmaceutical formulation
AR043201A1 (es) Composiciones de cementado y metodos de cementado en una formacion subterranea utilizando un aditivo para prevenir la segregacion de corpusculos ligeros
HUP0105160A2 (hu) Ras-farnezil transzferáz inhibitor és béta-ciklodextrin-7-szulfobutil-éter vagy 2-(hidroxi-propil)-béta-ciklodextrin komplexe és eljárás előállítására és ezeket tartalmazó gyógyszerkészítmények
RS50437B (sr) Benzoilpirazoli i njihova primena u ulozi herbicida
AR061815A1 (es) Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
CR10346A (es) Derivados de azabiciclo[3.1.0]hexil como modulares de los receptores de dopamina d3
AR067181A1 (es) Inhibidores de transcriptasa inversa de hiv, composicion farmaceutica, uso del compuesto para preparar un medicamento, agente de combinacion farmaceutica y metodo de inhibicion de la replicacion de un retrovirus
AR041053A1 (es) Derivados de dioxan-2-alquilcarbamatos, su preparacion y su aplicacion de terapeutica
MXPA03010445A (es) Derivados de 4(fenil-piperazinil-metil) benzamida y su uso para tratamiento del dolor, ansiedad o trastornos gastrointestinales.
AR023681A1 (es) Derivados de tetrahidrobenzazepinas, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento.
PE20060196A1 (es) Derivados de indol con actividad androgenica
WO2006071471A3 (en) 2-(2 or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
PE20020322A1 (es) Formulacion oral de rapida disolucion de un inhibidor de la ciclooxigenasa 2
SE0103313D0 (sv) Novel compounds
WO2007020411A8 (en) Amide derivatives
PE20010254A1 (es) Pesticidas a base de derivados de indazol o benzotriazol
DK1233953T3 (da) Nye benzoethiadiazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende samme
SE0201658D0 (sv) Immediate release pharmaceutical formulation
YU59201A (sh) Matrica koja se može direktno komprimovati, za kontrolisano oslobadjanje pojedinačnih dnevnih doza klaritromicina

Legal Events

Date Code Title Description
FC Refusal